Bellevue Group Ag Dynavax Technologies Corp Transaction History

Bellevue Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$11.7 - $14.98 $183,011 - $234,317	-15,642 Reduced 36.21%	27,558 $341,000
Q4 2023 Feb 14, 2024	SELL	$13.09 - $14.98 $523,600 - $599,200	-40,000 Reduced 48.08%	43,200 $603,000
Q3 2023 Nov 14, 2023	BUY	$12.64 - $14.99 $1.05 Million - $1.25 Million	83,200 New	83,200 $1.23 Million
Q3 2018 Nov 13, 2018	SELL	$11.85 - $16.0 $1.09 Million - $1.47 Million	-91,800 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$15.15 - $20.75 $40,905 - $56,025	-2,700 Reduced 2.86%	91,800 $1.4 Million
Q1 2018 May 09, 2018	BUY	$14.65 - $19.9 $578,675 - $786,050	39,500 Added 71.82%	94,500 $1.88 Million
Q4 2017 Feb 14, 2018	SELL	$17.3 - $24.08 $77,850 - $108,359	-4,500 Reduced 7.56%	55,000 $1.03 Million
Q3 2017 Nov 13, 2017	BUY	$15.2 - $21.5 $904,400 - $1.28 Million	59,500	59,500 $1.28 Million

273

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.6B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.